Financial Performance - Q3 2025 revenue reached ¥222,869,199.85, an increase of 3.78% year-over-year, while year-to-date revenue was ¥584,317,656.85, up 5.06% compared to the previous year[5] - Net profit attributable to shareholders was ¥6,344,040.03, down 51.73% year-over-year, and year-to-date net profit was ¥21,913,904.30, a decrease of 49.36%[5] - Basic earnings per share for the quarter was ¥0.0165, a decline of 52.03%, while year-to-date basic earnings per share was ¥0.0571, down 49.60%[5] - Total comprehensive income for the year-to-date was ¥23,471,634.26, down 47.83% from the previous year[11] - The net profit for the current period is CNY 23,867,516.19, a decrease of 47.4% compared to CNY 45,361,752.11 in the previous period[26] - The total profit for the current period is CNY 18,330,632.81, down from CNY 31,163,247.92, reflecting a decline of 41.3%[26] - Operating profit for the current period is CNY 18,609,104.55, compared to CNY 31,224,117.99 in the previous period, indicating a decrease of 40.8%[26] - The total comprehensive income for the current period is CNY 23,471,634.26, a decrease of 47.8% from CNY 44,992,255.06 in the previous period[26] Assets and Liabilities - Total assets increased to ¥1,587,919,783.62, reflecting a growth of 9.47% from the end of the previous year[5] - Total liabilities increased to ¥533,808,008.31 from ¥448,838,881.46, reflecting a growth of 19.0%[24] - The company's equity attributable to shareholders rose to ¥1,020,241,096.25 from ¥973,381,474.22, an increase of 4.8%[24] - Non-current assets totaled ¥663,301,584.37, slightly down from ¥670,313,529.45, a decrease of 1.5%[23] Cash Flow - Cash flow from operating activities for the year-to-date was ¥7,794,974.90, a significant increase of 148.60% compared to the same period last year[13] - Cash flow from operating activities shows a net inflow of CNY 7,794,974.90, a significant improvement from a net outflow of CNY 16,040,097.77 in the previous period[27] - Cash flow from investing activities resulted in a net outflow of CNY 151,446,023.16, slightly improved from CNY 186,702,227.12 in the previous period[28] - Cash flow from financing activities generated a net inflow of CNY 18,593,184.08, compared to a net outflow of CNY 62,737,410.37 in the previous period[28] Shareholder Information - The total number of common shareholders at the end of the reporting period is 29,555[14] - The largest shareholder, Wang Tingchun, holds 30.77% of the shares, amounting to 118,674,370 shares, with 26,603,600 shares pledged[14] - The number of shares with limited sales conditions held by Wang Tingchun is 89,005,777, which are locked for 36 months[16] - As of September 30, 2025, the company's total share capital has increased from 381,989,708 shares to 385,556,078 shares[18] Operational Highlights - The company has signed new business contracts worth approximately 1.248 billion RMB, representing a year-on-year growth of about 9.85%[17] - The company received three invention patents during the reporting period, including methods for the preparation of specific drugs[19] - The company obtained clinical trial approval for its drug "FCZR" from the National Medical Products Administration[18] - The company's governance structure has been optimized following the completion of the capital change registration[18] Costs and Expenses - Total operating costs amounted to ¥554,800,483.18, up from ¥519,937,507.73, reflecting a rise of 6.7%[25] - Research and development expenses decreased to ¥38,925,834.02 from ¥44,450,607.56, a decline of 12.4%[25] - The company's cash and cash equivalents decreased to ¥143,763,081.57 from ¥270,133,867.18, a decline of 46.8%[21] - Accounts receivable increased to ¥195,581,145.66 from ¥169,703,594.65, representing a growth of 15.2%[21] - Inventory rose to ¥242,017,600.69 from ¥189,485,440.64, marking an increase of 27.7%[21] Investment Income - The company experienced a 71.48% decrease in investment income, amounting to ¥422,611.89, mainly due to reduced financial product returns[11] - The company reported a 602.31% increase in trading financial assets, totaling ¥166,292,060.25, primarily due to the purchase of financial products[9] - Contract assets rose by 58.46% to ¥126,170,228.44, attributed to increased revenue during the period[9]

Core Points - The company Boji Pharmaceutical announced that its wholly-owned subsidiary, Guangzhou Huasheng Pharmaceutical Co., Ltd., has received the drug registration certificate from the National Medical Products Administration for "Compound Polyethylene Glycol Electrolyte Powder (III)" [2] Group 1 - The approval of the drug registration certificate marks a significant milestone for the company in expanding its product portfolio [2] - This development may enhance the company's market position in the pharmaceutical industry [2]

Core Viewpoint - The company Boji Pharmaceutical has received a drug registration certificate for its product, Compound Polyethylene Glycol Electrolyte Powder, from the National Medical Products Administration, indicating a significant regulatory milestone for the company [1] Group 1 - The product is intended for bowel cleansing preparation prior to endoscopic or radiological examinations and colon surgeries, highlighting its clinical application [1] - The registration certificate was issued to the company's wholly-owned subsidiary, Guangzhou Huasheng Pharmaceutical Co., Ltd., indicating the company's operational structure and focus on specialized subsidiaries [1]

Core Viewpoint - The approval of "Compound Polyethylene Glycol Electrolyte Powder (III)" by the National Medical Products Administration indicates a significant advancement for the company in the pharmaceutical market, particularly for bowel preparation in adults undergoing endoscopic or radiological examinations and colon surgeries [1] Company Summary - The subsidiary Guangzhou Huasheng Pharmaceutical Co., Ltd. has received the drug registration certificate for "Compound Polyethylene Glycol Electrolyte Powder (III)" [1] - This drug is specifically designed for bowel cleansing preparation in adult patients prior to endoscopic or radiological examinations and colon surgeries [1] Market Potential - According to data from Minet, the sales scale of "Compound Polyethylene Glycol Electrolyte Powder (III)" in urban and county-level public hospitals in China is approximately 220 million RMB in 2024 [1] - The approval signifies that the drug meets the national pharmaceutical review technical standards and can be produced and sold in the domestic market upon compliance with production quality management regulations [1]

博济医药科技股份有限公司 关于子公司获得药品注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：300404 证券简称：博济医药 公告编号：2025-079 近日，博济医药科技股份有限公司（以下简称"公司"）全资子公司广州华 圣制药有限公司申报的"复方聚乙二醇电解质散（Ⅲ）"获得国家药品监督管理 局核准签发的《药品注册证书》。现将相关情况公告如下： 一、 基本情况 药品名称：复方聚乙二醇电解质散（Ⅲ）（英文名/拉丁名：Polyethylene Glycol Electrolytes Powder（Ⅲ）） 剂型：散剂 规格：本品为复方制剂，每袋含：聚乙二醇 4000 64g，硫酸钠 5.7g，氯化钠 1.46g，氯化钾 0.75g，碳酸氢钠 1.68g 注册分类：化学药品 4 类 上市许可持有人：广州华圣制药有限公司 药品批准文号：国药准字 H20255557 药品批准文号有效期：至 2030 年 09 月 22 日 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。质量 ...

Core Viewpoint - Boji Pharmaceutical Technology Co., Ltd. disclosed the progress of share reduction by its controlling shareholder and related parties, indicating a decrease in their shareholding that has reached a 1% threshold [1][3]. Summary by Sections Reduction Plan Review - On August 22, 2025, Boji Pharmaceutical announced a share reduction plan involving its controlling shareholder Wang Tingchun and his concerted party, the Hengqin Guangjin Meihao Fund Management Co., Ltd. - Guangjin Meihao Fermi No. 13 Private Securities Investment Fund, intending to reduce up to 11,486,500 shares (3.00% of the total share capital excluding repurchased shares) within three months from September 12 to December 11, 2025 [2]. Reduction Progress - From September 12 to October 17, 2025, Fermi No. 13 reduced its holdings by 1,161,000 shares, representing 0.30% of the total share capital [3]. - Due to the exercise of stock options from the 2022 incentive plan, the total share capital increased, leading to a passive reduction of 0.02% in the shareholding percentage of Wang Tingchun, Fermi No. 13, and Zhao Lingli [3]. - The total shareholding of Wang Tingchun and his concerted parties decreased from 143,430,690 shares to 142,269,690 shares, reducing their ownership percentage from 37.20% to 36.88% [3]. Shareholding Structure Before and After - Before the reduction: - Wang Tingchun held 118,674,370 shares (30.78% of total share capital) - Fermi No. 13 held 5,536,700 shares (1.44%) - Zhao Lingli held 19,219,620 shares (4.98%) - Total: 143,430,690 shares (37.20%) - After the reduction: - Wang Tingchun held 118,674,370 shares (30.77%) - Fermi No. 13 held 4,375,700 shares (1.13%) - Zhao Lingli remained at 19,219,620 shares (4.98%) - Total: 142,269,690 shares (36.88%) [4]. Compliance and Impact of Reduction - The reduction plan complies with relevant laws and regulations, and it will not lead to a change in control of the company or significantly impact its ongoing operations [4]. - The company will continue to monitor the situation and fulfill its information disclosure obligations [4].

Core Viewpoint - 博济医药 has reported a significant share reduction by a major shareholder, which may impact the company's stock performance and investor sentiment [1] Shareholding Changes - The company received a notice from Fermi No. 13 regarding the reduction of shares, where Fermi No. 13 sold a total of 1.161 million shares between September 12, 2025, and October 17, 2025, representing 0.30% of the total share capital [1] - After this reduction, the controlling shareholder, Wang Tingchun, and his concerted action person, Zhao Lingli, along with Fermi No. 13, collectively hold 142 million shares, accounting for 36.88% of the total share capital [1] - The equity change triggered a 1% integer multiple threshold [1]

Core Viewpoint - The controlling shareholder of Boji Pharmaceutical, Wang Tingchun, along with his concerted parties, plans to reduce their shareholding through a centralized bidding process, impacting the overall shareholding structure of the company [1] Summary by Relevant Sections Shareholding Changes - Wang Tingchun and his concerted parties, Zhao Lingli and Feimi No. 13, will reduce their holdings by 1.161 million shares, which represents 0.30% of the company's total share capital [1] - Due to the exercise of stock options from the 2022 incentive plan, the total share capital of the company has increased, leading to a passive reduction of 0.02% in the shareholding percentage of Wang Tingchun, Feimi No. 13, and Zhao Lingli [1] Current Shareholding Status - After the equity change, the controlling shareholder and his concerted parties will hold a total of 14,226,970 shares, accounting for 36.88% of the company's total share capital [1] - The equity change has reached a threshold of 1% in terms of integer multiples [1] Implementation Status - The reduction plan has not yet been fully implemented [1]

证券代码：300404 证券简称：博济医药 公告编号：2025-078 博济医药科技股份有限公司 关于控股股东及其一致行动人减持股份进展暨权益变动触及 1%的公告 博济医药科技股份有限公司（以下简称"公司"）于 2025 年 8 月 22 日在巨 潮资讯网（www.cninfo.com.cn）上披露了《关于控股股东及其一致行动人减持股 份预披露公告》（公告编号：2025-062），公司控股股东、实际控制人王廷春先生 及其一致行动人横琴广金美好基金管理有限公司－广金美好费米十三号私募证 券投资基金（以下简称"费米十三号"）计划在上述公告披露之日起 15 个交易日 后的 3 个月内（即 2025 年 9 月 12 日至 2025 年 12 月 11 日），以大宗交易或集中 竞价的方式合计减持本公司股份不超过 11,486,500 股（占公司剔除回购专用证券 账户中股份数量后总股本的 3.00%）。 近日，公司收到费米十三号出具的《关于股份减持进展的告知函》，获悉费 米十三号在 2025 年 9 月 12 日至 2025 年 10 月 17 日期间，通过集中竞价减持公 司股票共计 1,161,000 股，占公司总股 ...

证券日报网讯 10月14日晚间，博济医药发布公告称，公司于2025年8月25日召开第五届董事会第十六次 会议以及于2025年9月12日召开2025年第一次临时股东大会，审议通过了《关于变更公司注册资本及修 订的议案》，同意公司变更注册资本，并根据相关规定及公司实际情况对《公司章程》中相关内容进行 修订。近日，公司完成了上述事项的工商变更登记及备案手续，取得了广州市市场监督管理局换发的 《营业执照》。 （编辑 任世碧） ...